Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs by Iwasa, T et al.
Marked anti-tumour activity of the combination of YM155, a novel
survivin suppressant, and platinum-based drugs
T Iwasa
1, I Okamoto*,1, K Takezawa
1, K Yamanaka
2, T Nakahara
2, A Kita
2, H Koutoku
2, M Sasamata
2,
E Hatashita
1, Y Yamada
1, K Kuwata
1, M Fukuoka
3 and K Nakagawa
1
1Department of Medical Oncology, Kinki University School of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan;
2Institute of Drug
Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan;
3Department of Medical Oncology, Kinki University
School of Medicine, Sakai Hospital, 2-7-1 Harayamadai, Minami-ku Sakai, Osaka 590-0132, Japan
BACKGROUND: Survivin, a member of the inhibitor of apoptosis protein family, is an attractive target for cancer therapy. We have now
investigated the effects of the combination of YM155, a novel small-molecule inhibitor of survivin expression, and platinum
compounds (cisplatin and carboplatin) on human non-small cell lung cancer (NSCLC) cell lines.
METHODS: The anti-cancer efficacy of YM155 in combination with platinum compounds was evaluated on the basis of cell death and
progression of tumour xenografts. Platinum compound-induced DNA damage was evaluated by immunofluorescence analysis of
histone g-H2AX.
RESULTS: Immunofluorescence analysis of histone g-H2AX showed that YM155 delayed the repair of double-strand breaks induced in
nuclear DNA by platinum compounds. The combination of YM155 and platinum compounds also induced synergistic increases both
in the number of apoptotic cells and in the activity of caspase-3. Finally, combination therapy with YM155 and platinum compounds
delayed the growth of NSCLC tumour xenografts in nude mice to an extent greater than that apparent with either treatment
modality alone.
CONCLUSION: These results suggest that YM155 sensitises tumour cells to platinum compounds both in vitro and in vivo, and that this
effect is likely attributable to the inhibition of DNA repair and consequent enhancement of apoptosis.
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Survivin is a 16.5-kDa member of the inhibitor of apoptosis
protein (IAP) family and blocks the mitochondrial pathway of
apoptosis by inhibiting caspases (Altieri, 2003a,b). Survivin also
regulates cell division through interaction with the proteins
INCENP and Aurora B (Wheatley et al, 2001). It is abundant in
many types of cancer cells but not in the corresponding normal
cells (Ambrosini et al, 1997; Marusawa et al, 2003; Altieri, 2004).
High levels of survivin expression in cancer cells are associated
with poor patient prognosis and survival, as well as with resistance
to therapy and an increased rate of cancer recurrence (Monzo et al,
1999; Altieri, 2001; Rodel et al, 2005). Survivin has therefore
become a therapeutic target and potentially important prognostic
marker for many tumour types including non-small cell lung
cancer (NSCLC) (Adida et al, 1998; Monzo et al, 1999). Reflecting
the many mechanisms that seem to regulate survivin expression,
diverse approaches have been evaluated for targeting survivin in
experimental models (Li et al, 1999; Olie et al, 2000; Grossman
et al, 2001).
YM155, a small imidazolium-based compound, was identified by
high-throughput screening of chemical libraries for inhibitors
of the activity of the survivin gene promoter in a reporter assay
(Nakahara et al, 2007). This compound specifically inhibits the
expression of survivin at both the mRNA and protein levels and
exhibits pronounced anti-cancer activity in pre-clinical models
(Nakahara et al, 2007). An advantage of YM155 compared with
previously investigated suppressors of survivin expression is that it
is active in the subnanomolar range (Carter et al, 2001; Milella
et al, 2001; O’Connor et al, 2002; De Schepper et al, 2003; Wall
et al, 2003; Sah et al, 2006). Our previous pharmacokinetics
analysis also revealed that YM155 becomes highly distributed to
tumour tissue in tumour xenograft models in vivo (Nakahara et al,
2007). In addition, continuous YM155 infusion in mice did not
result in systemic toxicity such as body weight loss or decreased
blood cell count (Nakahara et al, 2007). Furthermore, we have
recently shown that YM155 sensitised NSCLC cells to radiation
both in vitro and in vivo, and that this effect of YM155 was likely
attributable to the inhibition of DNA repair and enhancement of
apoptosis that result from downregulation of survivin expression
(Iwasa et al, 2008). YM155 is thus an attractive candidate drug for
cancer therapy.
Despite its demonstrated efficacy in targeting tumour cells, the
effects of YM155 in combination with DNA-damaging drugs have
remained largely unknown. We have now examined the effects of
the combination of YM155 and platinum compounds on human
NSCLC cell lines both in vitro and in vivo. Revised 4 May 2010; accepted 6 May 2010; published online 1 June 2010
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Cell culture and reagents
The human NSCLC cell lines NCI-H460 (H460), Calu6, NCI-H358
(H358), and PC14 were obtained from the American Type Culture
Collection (Manassas, VA, USA). The cells were cultured under an
atmosphere of 5% CO2 at 371C in RPMI 1640 medium (Sigma,
St Louis, MO, USA) supplemented with 10% foetal bovine serum.
Cisplatin (CDDP) was obtained from Nippon Kayaku (Tokyo,
Japan), and carboplatin (CBDCA) was from Bristol-Myers Squibb
(New York, NY, USA). YM155 (Astellas Pharma Inc, Tokyo, Japan)
was dissolved in dimethyl sulfoxide (DMSO).
Immunoblot analysis
Cells were washed twice with ice-cold phosphate-buffered saline
(PBS) and then lysed in a solution containing 20mM Tris–HCl
(pH 7.5), 150mM NaCl, 1mM EDTA, 1% Triton X-100, 2.5mM
sodium pyrophosphate, 1mM phenylmethylsulfonyl fluoride, and
leupeptin (1mgml
1). The protein concentration of lysates was
determined with the Bradford reagent (Bio-Rad, Hercules, CA,
USA), and equal amounts of protein were subjected to SDS
polyacrylamide gel electrophoresis on a 15% gel. The separated
proteins were transferred to a nitrocellulose membrane, which
was then exposed to 5% non-fat dried milk in PBS for 1h at room
temperature before overnight incubation at 41C with rabbit
polyclonal antibodies to human survivin (1:1000 dilution; R&D
Systems, Wiesbaden, Germany), to human c-IAP1 (1:1000 dilution;
MBL International, Woburn, MA, USA), or to human XIAP (1:1000
dilution; Cell Signaling, Beverly, MA). The membrane was then
washed with PBS containing 0.05% Tween 20 before incubation for
1h at room temperature with horseradish peroxidase-conjugated
goat antibodies to rabbit immunoglobulin G (Sigma). Immune
complexes were finally detected with chemiluminescence reagents
(PerkinElmer Life Science, Boston, MA, USA).
Detection of apoptotic cells
Cells were fixed with 4% paraformaldehyde for 1h at room
temperature, after which a minimum of 1000 cells per sample was
evaluated for apoptosis with the use of the terminal deoxynucleo-
tidyl transferase-mediated dUTP nick-end labelling (TUNEL)
technique (In situ Cell Death Detection Kit; Boehringer Mannheim,
Mannheim, Germany).
Assay of caspase-3 activity
The activity of caspase-3 in cell lysates was measured with
a CCP32/caspase-3 Fluometric Protease Assay Kit (MBL).
Fluorescence attributable to cleavage of the DEVD-AFC substrate
was measured at excitation and emission wavelengths of 390 and
460nm, respectively.
Immunofluorescence staining of c-H2AX
Cells were grown to 50% confluence in two-well Lab-Tec Chamber
Slides (Nunc, Naperville, IL, USA) and then cultured for 48h in the
presence of 50nM YM155 or vehicle (final DMSO concentration of
0.1%; we confirmed that this DMSO concentration did not affect
the proliferation of NSCLC cell lines) before additional exposure to
10mM CDDP or CBDCA. At various times thereafter, the cells were
fixed with 4% paraformaldehyde for 10min at room temperature,
permeabilised with 0.1% Triton X-100 for 10min at 41C, and
exposed to 5% non-fat dried milk for 10min at room temperature.
The slides were washed with PBS and then incubated at room
temperature first for 2h with mouse monoclonal antibodies to
histone g-H2AX (Upstate Biotechnology, Lake Placid, NY, USA) at
a dilution of 1:300 and then for 1h with Alexa Fluor 488-labeled
goat antibodies to mouse immunoglobulin G (Molecular Probes,
Eugene, OR, USA) at a dilution of 1:700. The slides were mounted
in fluorescence mounting medium (Dako Cytomation, Hamburg,
Germany), and fluorescence signals were visualised with a
confocal laser-scanning microscope (Axiovert 200M; Carl Zeiss,
Oberkochen, Germany) equipped with the LSM5 PASCAL system
(Carl Zeiss). Three random fields each containing at least 50 cells
were examined at a magnification of 100. Nuclei containing
X10 immunoreactive foci were counted as positive for g-H2AX,
and the percentage of positive cells was calculated (De Schepper
et al, 2003).
Evaluation of tumour growth in vivo
Male nude (BALB/cAnNCrj-nu/nu) mice (5 weeks old) were
obtained from Charles River Japan (Kanagawa, Japan). All animal
studies were performed in accordance with the Recommendations
for Handling of Laboratory Animals for Biomedical Research
compiled by the Committee on Safety and Ethical Handling
Regulations for Laboratory Animal Experiments, Kyoto University.
The ethical procedures followed met the requirements of the
UKCCCR guidelines (1998). Tumour cells (210
6) were implanted
into the right hind leg of 6-week-old male athymic nude mice.
Tumour volume was determined from caliper measurement of
tumour length (L) and width (W) according to the formula LW
2/2.
Treatment was initiated when tumours in each group of animals
achieved an average volume of 100–200mm
3. Treatment groups
(each containing eight mice) consisted of vehicle control (0.1%
DMSO in physiological saline), YM155 alone, vehicle plus CDDP or
CBDCA, and YM155 plus CDDP or CBDCA. Vehicle or YM155 at a
dose of 5mg per kg of body mass was administered over seven
consecutive days (days 0–6) with the use of an implanted micro-
osmotic pump (Alzet model 1007D; Durect, Cupertino, CA, USA).
CDDP (3mgkg
1) or CBDCA (60mgkg
1) was administered
intravenously on each of days 0–3 and days 7–11, respectively.
Statistical analysis
Data are presented as means±s.e. and were compared between
groups with the unpaired Student’s t-test. A P-value of o0.05 was
considered statistically significant.
RESULTS
Specific inhibition of survivin expression in NSCLC cells
by YM155
We first examined the effect of YM155 on survivin expression in
human NSCLC cell lines by immunoblot analysis. Exposure of
H460, Calu6, H358, or PC14 cells to YM155 at 10–100nM for 48h
inhibited survivin expression in a concentration-dependent
manner (Figure 1A). In contrast, exposure of these cell lines to
YM155 at 50nM for 48h did not affect the abundance of other
members of the IAP family including XIAP and c-IAP1
(Figure 1B), indicating that YM155 specifically inhibits survivin
expression in the NSCLC cell lines.
Enhancement of DNA-damaging agent-induced apoptosis
in NSCLC cells by YM155
We next examined the effect of YM155 on DNA-damaging agent-
induced apoptosis in H460, Calu6, H358, or PC14 cells with the use
of the TUNEL assay. Combined treatment of each cell line with
YM155 and either CDDP or CBDCA resulted in an increase in the
number of apoptotic cells at 24 and 48h that was greater than the
sum of the increases induced by YM155 or by CDDP or CBDCA
alone (Figure 2). To confirm the results of the TUNEL assay, we
measured the activity of caspase-3 in cell lysates. Again, combined
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either CDDP or CBDCA induced a synergistic increase in caspase-3
activity (Figure 2). These data thus suggested that YM155
promotes the induction of apoptosis by DNA-damaging agents
in NSCLC cell lines.
Effect of YM155 in combination with DNA-damaging
agents on H2AX phosphorylation
We have previously shown that YM155 sensitises tumour cells to
radiation by inhibiting the repair of radiation-induced DNA
damage. CDDP and CBDCA are key drugs in NSCLC treatment and
are known to induce DNA damage (Diggle et al, 2005). We
therefore hypothesised that YM155 might inhibit the repair of
CDDP- or CBDCA-induced DNA damage and thereby promote
CDDP- or CBDCA-induced cell death. To explore this possibility,
we determined whether YM155 might affect CDDP- or CBDCA-
induced phosphorylation of histone H2AX to yield g-H2AX, which
is a marker of DNA double-strand breaks (DSBs). Exposure of
H460 or Calu6 cells to CDDP or CBDCA resulted in the gradual
accumulation of g-H2AX foci, with this effect being maximal at
12h, after which the number of foci declined (Figure 3). Although
YM155 did not affect the extent of CDDP- or CBDCA-induced
focus formation, it significantly retarded the loss of foci normally
apparent at 24h after exposure to CDDP or CBDCA (Figure 3).
These results thus suggested that downregulation of survivin
expression by YM155 results in inhibition of the repair of DSBs
induced by DNA-damaging agents in NSCLC cells.
Enhancement of chemotherapy-induced tumour regression
by YM155
To determine whether the enhancement of the anti-tumour activity
of DNA-damaging agents by YM155 observed in vitro might also
be apparent in vivo, we injected Calu6 cells into nude mice to elicit
the formation of solid tumours. After tumour formation, the
mice were treated with YM155, CDDP, or both drugs. Combined
treatment with CDDP and YM155 inhibited Calu6 tumour growth
to a markedly greater extent than did treatment with either drug
alone (Figure 4A). No pronounced tissue damage or toxicity such
as weight loss (Figure 4A) was observed in mice in any of the four
treatment groups.
Finally, we examined the effect of the combination of
YM155 and CBDCA on tumour growth. Treatment with YM155
or CBDCA alone delayed tumour growth, whereas combined
treatment inhibited tumour growth to a significantly greater extent
(Figure 4B). Again, there was no evidence of toxicity on the basis of
body weight loss (Figure 4B) and there were no animal deaths in
any of the four groups. These data suggested that YM155 enhances
the tumour response to platinum-based chemotherapy in vivo.
DISCUSSION
The success of anti-cancer therapies is often limited by the
development of resistance to apoptosis, which may result from
defects in common apoptotic pathways (Hanahan and Weinberg,
2000). In this context, approaches to counteract the action of
H460
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Control
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PC14 H358
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Figure 1 Effect of YM155 on survivin expression in human non-small cell lung cancer (NSCLC) cells. (A) H460, Calu6, H358, or PC14 cells were
incubated in the absence (control, 0.1% dimethyl sulfoxide (DMSO)) or presence of the indicated concentrations of YM155 for 48h. Cell lysates were then
prepared and subjected to immunoblot analysis with antibodies to survivin or to b-actin (loading control). (B) H460, Calu6, H358, or PC14 cells were
incubated in the absence or presence of 50nM YM155 for 48h, after which cell lysates were subjected to immunoblot analysis with antibodies to survivin,
c-IAP1, XIAP, or b-actin.
Combined effect of YM155 and platinum compounds
T Iwasa et al
38
British Journal of Cancer (2010) 103(1), 36–42 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
ssurvivin in tumour cells have been proposed with the dual aims of
inhibiting tumour growth through promotion of spontaneous
apoptosis and of enhancing the tumour cell response to apoptosis-
inducing agents (Altieri, 2003b). In this study, we found that the
combination of YM155 and platinum compounds induced NSCLC
cell apoptosis as well as the activation of caspase-3 to an extent
greater than that apparent with either type of agent alone. Our
findings thus suggest that YM155 acts in a synergistic manner to
promote the induction of apoptosis by platinum compounds.
Cellular responses to stress or DNA damage are important for
the maintenance of genomic stability and cellular integrity (Bunz
et al, 1998; Hirao et al, 2000). Depending on its extent, cells either
repair DNA damage or, when it is too severe for repair, initiate the
cell death programme (Zhao et al, 2001). Agents that inhibit repair
of DNA damage therefore increase the sensitivity of cells to
ionising radiation and chemotherapeutic drugs (Banath et al, 2004;
Taneja et al, 2004). The chemotherapeutic effect of platinum
compounds results from their interaction with DNA; platinum
thus induces the formation of DNA–protein crosslinks, DNA
monoadducts, as well as interstrand or intrastrand DNA crosslinks
(Chu, 1994; Siddik, 2003). These DNA adducts induce local
distortion in the DNA double helix that results in strand
unwinding and kinking (Chu, 1994). Survivin was previously
shown to enhance tumour cell survival after radiation exposure
through regulation of DSB repair (Chakravarti et al, 2004). We
have previously shown that YM155 inhibited the repair of
radiation-induced DSBs in NSCLC cells and that this effect likely
accounted for the observed radiosensitising action of YM155
(Iwasa et al, 2008). We therefore investigated the effect of YM155
on the repair of platinum compound-induced DSBs by immuno-
fluorescence imaging of g-H2AX foci. Given that g-H2AX appears
rapidly at DNA DSBs and disappears as repair proceeds (Rogakou
et al, 1998; Zhou and Elledge, 2000; Khanna et al, 2001; Shiloh and
Kastan, 2001), it serves as a sensitive and specific marker for
unrepaired DNA damage. We found that YM155 inhibited the
repair of platinum compound-induced DSBs in NSCLC cells.
Overexpression of survivin was previously shown to enhance DSB
repair in tumour cells through upregulation of Ku protein (Jiang
et al, 2009). Although it remains unclear whether YM155 affects Ku
protein kinetics, our data suggest that the observed chemosensi-
tisation by YM155 is attributable to inhibition of the repair of DNA
damage induced by CDDP or CBDCA. Further investigations will
be required to determine the mechanism underlying the effect of
YM155 on DNA repair.
In addition to the initially identified isoform, four splice variants
of human survivin have been described: survivin-2a, survivin-2b,
survivin-d-Ex3, and survivin-3b (Mahotka et al, 1999, 2002; Badran
et al, 2004; Caldas et al, 2005a). However, little is known of
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Figure 2 Effects of YM155 on DNA-damaging agent-induced apoptosis and caspase-3 activity in H460, Calu6, H358, or PC14 cells. Cells were incubated
with 50nM YM155 or vehicle (0.1% dimethyl sulfoxide (DMSO)) for 48h and then for the indicated times (upper panels) or for 24h (lower panels) in the
additional absence or presence of 10mM CDDP (A) or CBDCA (B). The percentage of apoptotic cells was then determined by terminal deoxynucleotidyl
transferase-mediated dUTP nick-end labeling (TUNEL) staining (upper panels), and cell lysates were assayed for caspase-3 activity (lower panels). All data
are means±s.e. from three independent experiments; those for caspase-3 activity are expressed relative to the corresponding value for the control
condition. *Po0.05, **Po0.001, ***Po0.0001 vs the corresponding value for CDDP or CBDCA or for YM155 alone.
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survivin (Krieg et al, 2002; Mahotka et al, 2002; Caldas et al, 2005b;
Noton et al, 2006). Given that the suppression of survivin
expression by YM155 is mediated through inhibition of the
transcriptional activity of the survivin gene promoter (Nakahara
et al, 2007), it is possible that YM155 also inhibits the expression
of these survivin variants.
No serious adverse haematological events related to drug
treatment were reported in phase I studies of YM155 in single-
agent therapy (Tolcher et al, 2008; Satoh et al, 2009). A recent
phase II study showed that YM155 monotherapy is safe but only
moderately effective (objective tumour response rate, 5.4%) in
patients with advanced NSCLC (Giaccone et al, 2009). Given this
limited efficacy of YM155 as a single agent in NSCLC patients, the
combination of YM155 with other agents may be beneficial.
Platinum-based combination chemotherapy is the standard
of care for most individuals with advanced NSCLC (Chu, 1994).
We have shown that treatment of NSCLC cells with YM155
results in a marked increase in the anti-tumour effects of CDDP
and CBDCA both in vitro and in vivo, suggesting that the
combination of YM155 and platinum compounds may have
potential as a novel therapeutic regimen. Clinical studies of
YM155 in combination with platinum-based chemotherapy are
thus warranted.
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Figure 4 Effects of YM155 on the anti-tumour action of CDDP or CBDCA in vivo. Calu6 cells were injected into the right hind limb of nude mice and
allowed to form tumours, after which the mice were assigned to one of four treatment groups (control, CDDP (A) or CBDCA (B) alone, YM155 alone, or
the combination of YM155 and either CDDP (A) or CBDCA (B)) as described in Materials and Methods. Tumour volume was measured at the indicated
times after the onset of treatment (left panels); values for mice in the control group are not shown for later time points to highlight differences among the
other three groups. Body weight was also measured in each treatment group at the indicated times and is expressed relative to the corresponding value for
time 0 (right panels). All data are means±s.e. from eight mice per group. *Po0.0001 vs the corresponding value for treatment with CDDP (A) or CBDCA
(B) alone or with YM155 alone.
Figure 3 Effect of YM155 on the formation of g-H2AX foci induced by DNA-damaging agents in non-small cell lung cancer (NSCLC) cells. (A) H460 cells
were incubated with vehicle (0.1% dimethyl sulfoxide (DMSO)) or 50nM YM155 for 48h and then for the indicated times in the additional absence
or presence of 10mM CDDP or CBDCA . The cells were then fixed and subjected to immunofluorescence staining for g-H2AX (green fluorescence).
(B) H460 or Calu6 cells were incubated with vehicle or 50nM YM155 for 48h and then for the indicated times in the additional absence or presence
of 10mM CDDP or CBDCA . They were then fixed and subjected to immunofluorescence staining for g-H2AX, and the percentage of cells containing
g-H2AX foci was determined. Data are means±s.e. from three independent experiments. *Po0.05, **Po0.001 vs the corresponding value for
CDDP or CBDCA alone.
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